Is YKL-40 a new therapeutic target in cancer?

被引:61
作者
Johansen, Julia S.
Jensen, Benny Vittrup
Roslind, Anne
Price, Paul A.
机构
[1] Univ Copenhagen, Herlev Hosp, Dept Rheumatol Q107, DK-2730 Herlev, Denmark
[2] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[3] Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA
关键词
biomarker; cancer target; CHI3L1; prognosis; YKL-40;
D O I
10.1517/14728222.11.2.219
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
YKL-40 is produced by cancer cells and tumour-associated macrophages. YKL-40 may play a role in cancer cell proliferation, differentiation, survival, invasiveness, metastasis, in angiogenesis and the inflammation and remodelling of the extracellular matrix surrounding the tumour. Serum YKL-40 is a biomarker of prognosis, confirmed in 13 different types of cancer including > 2500 patients. Highest serum YKL-40 is found in patients with metastatic cancer with the shortest recurrence-free interval and shortest overall survival. Serum YKL-40 provides independent information compared with clinical characteristics and biomarkers, such as HER2, carcinoembryonic antigen, CA-125, prostate-specific antigen and lactate dehydrogenase. The authors hypothesise that inhibition of YKL-40 by monoclonal antibodies either directly or towards its receptor may be as efficient a cancer therapeutic as the monoclonal antibodies against HER2, HER1, vascular endothelial growth factor and CD20. Drugs inhibiting YKL-40 should be explored as new cancer therapeutics.
引用
收藏
页码:219 / 234
页数:16
相关论文
共 147 条
[1]   COMPLEMENTARY DEOXYRIBONUCLEIC-ACID CLONING AND MOLECULAR CHARACTERIZATION OF AN ESTROGEN-DEPENDENT HUMAN OVIDUCTAL GLYCOPROTEIN [J].
ARIAS, EB ;
VERHAGE, HG ;
JAFFE, RC .
BIOLOGY OF REPRODUCTION, 1994, 51 (04) :685-694
[2]   Homology modeling of glycosyl hydrolase family 18 enzymes and proteins [J].
Aronson, NN ;
Blanchard, CJ ;
Madura, JD .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1997, 37 (06) :999-1005
[3]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[4]  
Baeten D, 2000, ARTHRITIS RHEUM, V43, P1233, DOI 10.1002/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO
[5]  
2-9
[6]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[7]   Cancer - An inflammatory link [J].
Balkwill, F ;
Coussens, LM .
NATURE, 2004, 431 (7007) :405-406
[8]   The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF [J].
Belge, KU ;
Dayyani, F ;
Horelt, A ;
Siedlar, M ;
Frankenberger, M ;
Frankenberger, B ;
Espevik, T ;
Ziegler-Heitbrock, L .
JOURNAL OF IMMUNOLOGY, 2002, 168 (07) :3536-3542
[9]   Molecular analysis of expansion, differentiation, and growth factor treatment of human chondrocytes identifies differentiation markers and growth-related genes [J].
Benz, K ;
Breit, S ;
Lukoschek, M ;
Mau, H ;
Richter, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (01) :284-292
[10]   High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia [J].
Bergmann, OJ ;
Johansen, JS ;
Klausen, TW ;
Mylin, AK ;
Kristensen, JS ;
Kjeldsen, E ;
Johnsen, HE .
CLINICAL CANCER RESEARCH, 2005, 11 (24) :8644-8652